A systematic study on the utility of CHX-A’’-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177 Lu radiopharmaceuticals-Reference-Cited by-同舟云学术

A systematic study on the utility of CHX-A’’-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177 Lu radiopharmaceuticals

Published:2017-09 Issue: Volume:127 Page:1-6
ISSN:0969-8043
Container-title:Applied Radiation and Isotopes
language:en
Short-container-title:Applied Radiation and Isotopes

Author:

Pandey Usha,Gamre Naresh,Lohar Sharad Pandurang,Dash Ashutosh

Publisher

Elsevier BV

Subject

Radiation

Reference30 articles.

1. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry and practical applications;Banerjee;Chem. Rev.,2015

2. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies;Camera;J. Nucl. Med.,1994

3. Tracer level radiochemistry to clinical dose preparation of 177Lu-labeled cyclic RGD peptide dimer;Chakraborty;Nucl. Med. Biol.,2013

4. On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience;Chakraborty;J. Radioanal. Nucl. Chem.,2014

5. Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor;Chakraborty;J. Label. Comp. Radiopharm.,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside;Theranostics;2024

2. Design and synthesis of a new bifunctional chelating agent: Application for Al 18F/177Lu complexation;Journal of Inorganic Biochemistry;2023-09

3. Аpproaches to the production of theranostic couples of radiopharmaceuticals for the diagnosis and treatment of prostate cancer: a literature review;Russian Journal for Personalized Medicine;2023-07-28

4. Preparation of 177Lu Using Vacuum Sublimation Technology;Radiochemistry;2023-04

5. Unravelling the Potential of Lutetium-177 Labeled Pertuzumab: Targeting HER 2 Receptors for Theranostic Applications;International Journal of Radiation Oncology*Biology*Physics;2023-02